

Please staple your
payment here請將股款
緊釘在此

This Application Form uses the same terms as defined in the prospectus of WuXi XDC Cayman Inc. (the “Company”) dated November 7, 2023 (the “Prospectus”).

本申請表格使用藥明合聯生物技術有限公司*（「本公司」）於2023年11月7日刊發的招股章程（「招股章程」）所界定的相同詞語。

Neither this Application Form nor the Prospectus constitutes an offer to sell or the solicitation of an offer to buy any Offer Shares in any jurisdiction in which such offer, solicitation or sales would be unlawful. The Offer Shares may not be offered or sold in the United States without registration or an exemption from registration under the U.S. Securities Act.

本申請表格及招股章程概不構成在進行要約、游說或出售發售股份即屬違法的任何司法管轄區要約出售或游說要約購買任何發售股份。若無根據美國證券法登記或獲豁免登記，發售股份不得在美國提呈發售或出售。

This Application Form and the Prospectus may not be forwarded or distributed or reproduced (in whole or in part) in any manner whatsoever in any jurisdiction where such forwarding, distribution or reproduction is not permitted under the law of that jurisdiction.

任何根據當地法例不得發送、派發或複製本申請表格及招股章程的司法管轄區內概不得發送或派發或複製（不論方式，也不論全部或部分）本申請表格及招股章程。

Copies of the Prospectus, all related Application Forms and the other documents specified in the “Documents Delivered to the Registrar of Companies in Hong Kong and on Display – 1. Documents Delivered to the Registrar of Companies in Hong Kong” section in Appendix V to the Prospectus, have been registered by the Registrar of Companies in Hong Kong as required by section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong), Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange”), Hong Kong Securities Clearing Company Limited (“HKSCC”), the Securities and Futures Commission of Hong Kong (the “SFC”) and the Registrar of Companies in Hong Kong take no responsibility for the contents of these documents.

招股章程、所有相關申請表格及招股章程附錄五「送呈香港公司註冊處處長及展示文件 – 1. 送呈香港公司註冊處處長文件」一節所述其他文件已根據香港法例第32章公司（清盤及雜項條文）條例第342C條規定送呈香港公司註冊處處長登記。香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）、香港中央結算有限公司（「香港結算」）、香港證券及期貨事務監察委員會（「證監會」）及香港公司註冊處處長對此等文件的內容概不負責。

**WuXi XDC Cayman Inc.****藥明合聯生物技術有限公司****(Incorporated in the Cayman Islands with limited liability)**(於開曼群島註冊成立的有限公司)***Stock Code : 2268****股份代號 : 2268****Maximum Offer Price : HK\$20.60 per Share, plus brokerage of 1%,
SFC transaction levy of 0.0027%, the Stock
Exchange trading fee of 0.00565% and
AFRC Transaction Levy of 0.00015%
(payable in full on application in
Hong Kong dollars and subject to refund)****最高發售價：每股股份20.60港元，另加1%經紀佣金、
0.0027%證監會交易徵費、0.00565%聯交所
交易費及0.00015%會財局交易徵費
(須於申請時以港元繳足，多繳款項可予退還)****Applicants' declaration**

I/We agree to the terms and conditions and application procedures in this Application Form and the Prospectus. Please refer to the “D. Effect of completing and submitting this Application Form” section of this Application Form.

Warning: Only one application may be made for the benefit of any person for Reserved Shares on a BLUE Application Form. The following are liable to be rejected: multiple or suspected multiple applications for Reserved Shares and applications where cheques or banker's cashier orders are dishonoured upon the first presentation.

* For identification purpose only

申請人聲明

本人／我們同意本申請表格及招股章程的條款及條件以及申請程序。請參閱本申請表格「丁.填交本申請表格的效用」一節。

警告：任何人士僅可為本身利益以藍色申請表格就預留股份作出一次申請。下列情況將不獲受理：就預留股份作出的重複或疑屬重複申請以及支票或銀行本票在首次過戶時未能兌現的申請。

* 僅供識別

BLUE Form 藍表 (Assured Entitlement 保證配額)
Please use this Application Form if you are a Qualifying WXB Shareholder
 閣下如為合資格藥明生物技術股東，請使用本申請表格

Name(s) and address of the Qualifying WXB Shareholder
 合資格藥明生物技術股東姓名／名稱及地址

User ID 使用者編號

Access Code 通行編號

CCS6442

| | | |
|--|---|---|
| <p>Apply for Assured Entitlement of Reserved Shares You may apply for a number of Reserved Shares pursuant to your Assured Entitlement that is equal to or less than the number stated in Box B. If you intend to apply for a number of Reserved Shares that is less than your Assured Entitlement, you MUST apply for a number which is one of the numbers set out in the table below (other than HKSCC Nominees). If you wish to apply for excess Reserved Shares in addition to your Assured Entitlement, you should complete and sign the Blue Application Form for excess Reserved Shares and lodge it, together with a separate remittance for the full amount payable on application in respect of the excess Reserved Shares applied for. You need to complete and sign this Application Form and submit one cheque (or banker's cashier order) for the exact amount of remittance printed in Box B on the right or in the table below.</p> <p>申請保證配額之預留股份 閣下可根據保證配額申請相等或少於乙欄列明數目的預留股份。倘閣下擬申請的預留股份數目少於閣下的保證配額，閣下必須申請下表中所載列的其中一個數目（香港結算代理人除外）。倘閣下擬申請保證配額以外的超額預留股份，則須交回經填妥並簽署的申請超額預留股份之藍色申請表格，並單獨匯款足額支付所申請超額預留股份的應付股款。 閣下須填妥及簽署本申請表格並提交一張支票（或銀行本票）支付於右方乙欄或下表列明的應付確切金額。</p> | <p>Box A 甲欄</p> <p>Number of WXB Shares registered in your name as at 4:30 p.m. on Monday, November 6, 2023 (the "Record Date"); 於2023年11月6日（星期一）（「記錄日期」）下午四時三十分以閣下名義登記之藥明生物技術股份數目：</p> | |
| | <p>Box B 乙欄</p> <p>Number of Reserved Shares in your Assured Entitlement: 閣下所獲保證配額之預留股份數目：</p> | <p>Amount payable if your Assured Entitlement is taken up in full: 閣下保證配額獲全數接納應付之款項：</p> |
| | | HKS 港元 |

| WuXi XDC Cayman Inc. 藥明合聯生物技術有限公司 (Stock Code 股份代號 2268) (HK\$20.60 per Reserved Share 每股預留股份 20.60 港元) NUMBER OF RESERVED SHARES THAT MAY BE APPLIED FOR AND PAYMENTS 可供申請認購預留股份數目及應繳款項 | | | | | |
|---|---|---|---|---|---|
| No. of Reserved Shares applied for 申請認購的預留股份數目 | Amount payable on application 申請時應繳款項 HKS 港元 | No. of Reserved Shares applied for 申請認購的預留股份數目 | Amount payable on application 申請時應繳款項 HKS 港元 | No. of Reserved Shares applied for 申請認購的預留股份數目 | Amount payable on application 申請時應繳款項 HKS 港元 |
| 500 | 10,403.88 | 7,000 | 145,654.26 | 50,000 | 1,040,387.56 |
| 1,000 | 20,807.75 | 8,000 | 166,462.01 | 60,000 | 1,248,465.05 |
| 1,500 | 31,211.63 | 9,000 | 187,269.77 | 70,000 | 1,456,542.56 |
| 2,000 | 41,615.50 | 10,000 | 208,077.51 | 80,000 | 1,664,620.08 |
| 2,500 | 52,019.38 | 15,000 | 312,116.26 | 90,000 | 1,872,697.59 |
| 3,000 | 62,423.25 | 20,000 | 416,155.02 | 100,000 | 2,080,775.10 |
| 3,500 | 72,827.13 | 25,000 | 520,193.78 | 125,000 | 2,600,968.88 |
| 4,000 | 83,231.00 | 30,000 | 624,232.54 | 150,000 | 3,121,162.66 |
| 4,500 | 93,634.88 | 35,000 | 728,271.29 | 175,000 | 3,641,356.43 |
| 5,000 | 104,038.75 | 40,000 | 832,310.05 | 200,000 | 4,161,550.20 |
| 6,000 | 124,846.51 | 45,000 | 936,348.80 | 225,000 | 4,681,743.98 |
| | | | | 250,000 | 5,201,937.76 |
| | | | | 500,000 | 10,403,875.50 |
| | | | | 750,000 | 15,605,813.26 |
| | | | | 1,000,000 | 20,807,751.00 |
| | | | | 2,000,000 | 41,615,502.00 |
| | | | | 3,000,000 | 62,423,253.00 |
| | | | | 4,000,000 | 83,231,004.00 |
| | | | | 5,000,000 | 104,038,755.00 |
| | | | | 6,000,000 | 124,846,506.00 |
| | | | | 7,000,000 | 145,654,257.00 |
| | | | | 8,922,000 | 185,646,754.43 |

Write down the number of Assured Entitlement you want to apply for and the total amount payable in the following appropriate boxes in ink (preferably in black) and mark "X" in the corresponding boxes underneath.
 請在以下適當空格內用墨水筆（以黑色為佳）填寫閣下擬申請之保證配額數目及應繳總額，並在相應空格內標上「X」。

| Number of Assured Entitlement applied for 申請認購的保證配額數目 | | | | | | | | | | Total amount of remittance (HK\$) 付款總額 (港元) | | | | | | | | | | |
|--|---|---|---|---|---|---|---|---|---|--|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 |
| 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |

You must pay for the Reserved Shares applied for pursuant to your Assured Entitlement by a separate cheque or banker's cashier order.
 閣下必須以獨立開出的支票或銀行本票支付根據閣下的保證配額所申請的預留股份。
 * Cheque or banker's cashier order should be crossed "Account Payee Only" and made payable to "BANK OF CHINA (HONG KONG) NOMINEES LIMITED – WUXI XDC PREFERENTIAL OFFER". The applicant's name/the first applicant's name on the joint application must be the same as the name pre-printed or certified/endorsed by the drawee bank on the cheque/banker's cashier order.
 * 支票或銀行本票須以「只准入抬頭人賬戶」方式劃線開出，並須註明抬頭人為「中國銀行（香港）代理人有限公司 - 藥明合聯生物技術優先發售」。申請人姓名／名稱／聯名申請排名首位申請人的姓名／名稱須與在支票／銀行本票的預印名稱或付款銀行核證／背面簽署的名稱相同。

Cheque/Banker's cashier order number*
 支票／銀行本票號碼* _____
 Name of bank on which cheque/banker's cashier order is drawn*
 支票／銀行本票之付款銀行名稱* _____
 Contact telephone no.
 聯絡電話號碼 _____

Signed by (all) applicant(s) (all joint applicants must sign):
 由(所有)申請人簽署(所有聯名申請人必須簽署):

You (or, if you are joint applicants, the first-named applicant) must provide your Hong Kong identity card number/passport number/Hong Kong business registration certificate number (Please delete as appropriate)
 閣下或(倘閣下為聯名申請人)排名首位申請人必須提供香港身份證號碼／護照號碼／香港商業登記號碼(請刪除不適用者) _____

Date 日期: _____ / _____ / _____
 D 日 M 月 Y 年

Please staple your
payment here

請將股款
緊釘在此

This Application Form uses the same terms as defined in the prospectus of WuXi XDC Cayman Inc. (the “Company”) dated November 7, 2023 (the “Prospectus”).
本申請表格使用藥明合聯生物技術有限公司* (「本公司」) 於2023年11月7日刊發的招股章程 (「招股章程」) 所界定的相同詞語。

Neither this Application Form nor the Prospectus constitutes an offer to sell or the solicitation of an offer to buy any Offer Shares in any jurisdiction in which such offer, solicitation or sales would be unlawful. The Offer Shares may not be offered or sold in the United States without registration or an exemption from registration under the U.S. Securities Act.

本申請表格及招股章程概不構成在進行要約、游說或出售發售股份即屬違法的任何司法管轄區要約出售或游說要約購買任何發售股份。若無根據美國證券法登記或獲豁免登記，發售股份不得在美國提呈發售或出售。This Application Form and the Prospectus may not be forwarded or distributed or reproduced (in whole or in part) in any manner whatsoever in any jurisdiction where such forwarding, distribution or reproduction is not permitted under the law of that jurisdiction.

任何根據當地法例不得發送、派發或複製本申請表格及招股章程的司法管轄區內概不得發送或派發或複製 (不論方式，也不論全部或部分) 本申請表格及招股章程。

Copies of the Prospectus, all related Application Forms and the other documents specified in the “Documents Delivered to the Registrar of Companies in Hong Kong and on Display – 1. Documents Delivered to the Registrar of Companies in Hong Kong” section in Appendix V to the Prospectus, have been registered by the Registrar of Companies in Hong Kong as required by section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong), Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange”), Hong Kong Securities Clearing Company Limited (“HKSCC”), the Securities and Futures Commission of Hong Kong (the “SFC”) and the Registrar of Companies in Hong Kong take no responsibility for the contents of these documents.

招股章程、所有相關申請表格及招股章程附錄五「送呈香港公司註冊處處長及展示文件 – 1. 送呈香港公司註冊處處長文件」一節所述其他文件已根據香港法例第32章公司 (清盤及雜項條文) 條例第342C條規定送呈香港公司註冊處處長登記。香港交易及結算所有限公司、香港聯合交易所有限公司 (「聯交所」)、香港中央結算有限公司 (「香港結算」)、香港證券及期貨事務監察委員會 (「證監會」) 及香港公司註冊處處長對此等文件的內容概不負責。



WuXi XDC Cayman Inc.

藥明合聯生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(於開曼群島註冊成立的有限公司)

Stock Code : 2268

股份代號 : 2268

Maximum Offer Price : HK\$20.60 per Share, plus brokerage of 1%,

SFC transaction levy of 0.0027%,

the Stock Exchange trading fee of 0.00565%

and AFRC Transaction Levy of 0.00015%

(payable in full on application in

Hong Kong dollars and subject to refund)

最高發售價：每股股份20.60港元，另加1%經紀佣金、

0.0027%證監會交易徵費、0.00565%聯交所

交易費及0.00015%會財局交易徵費

(須於申請時以港元繳足，多繳款項可予退還)

Applicants' declaration

I/We agree to the terms and conditions and application procedures in this Application Form and the Prospectus. Please refer to the “D. Effect of completing and submitting this Application Form” section of this Application Form.

Warning: Only one application may be made for the benefit of any person for Reserved Shares on a BLUE Application Form. The following are liable to be rejected: multiple or suspected multiple applications for Reserved Shares and applications where cheques or banker's cashier orders are dishonoured upon the first presentation.

申請人聲明

本人/我們同意本申請表格及招股章程的條款及條件以及申請程序。請參閱本申請表格「丁.填交本申請表格的效用」一節。

警告：任何人士僅可為本身利益以藍色申請表格就預留股份作出一次申請。下列情況將不獲受理：就預留股份作出的重複或疑屬重複申請以及支票或銀行本票在首次過戶時未能兌現的申請。

BLUE Form 藍表 (Excess Application 超額申請)
Please use this Application Form if you are a Qualifying WXB Shareholder
閣下如為合資格藥明生物技術股東，請使用本申請表格

Name(s) and address of the Qualifying WXB Shareholder
合資格藥明生物技術股東姓名/名稱及地址

User ID 使用者編號

Access Code 通行編號

CCS6442

Apply for Excess Reserved Shares

Other than Assured Entitlement, you may apply for excess Reserved Shares. If you intend to apply for excess Reserved Shares, you MUST apply for a number of excess Reserved Shares which is one of the numbers set out in the table below (other than HKSCC Nominees). If you wish to apply for excess Reserved Shares in addition to your Assured Entitlement, you should complete and sign the Blue Application Form for excess Reserved Shares and lodge it, together with a separate remittance for the full amount payable on application in respect of the excess Reserved Shares applied for. You need to complete and sign this Application Form and submit one cheque (or banker's cashier order) for the exact amount of remittance in the table below.

申請認購預留股份

除保證配額外，閣下亦可申請超額預留股份。倘閣下擬申請超額預留股份，閣下必須申請下表中載列的其中一個超額預留股份數目(香港結算代理人除外)。倘閣下擬申請保證配額外之超額預留股份，則須交回經填妥並簽署的申請超額預留股份之藍色申請表格，並單獨匯款足額支付所申請超額預留股份的應付股款。閣下須填妥及簽署本申請表格並提交一張支票(或銀行本票)支付下表中載列的應付確切金額。

WuXi XDC Cayman Inc. 藥明合聯生物技術有限公司 (Stock Code 股份代號 2268)
(HK\$20.60 per Reserved Share 每股預留股份 20.60 港元)
NUMBER OF RESERVED SHARES THAT MAY BE APPLIED FOR AND PAYMENTS
可供申請認購預留股份數目及應繳款項

Table with 6 columns: No. of Reserved Shares applied for, Amount payable on application (HK\$), No. of Reserved Shares applied for, Amount payable on application (HK\$), No. of Reserved Shares applied for, Amount payable on application (HK\$), No. of Reserved Shares applied for, Amount payable on application (HK\$).

Write down the number of excess Reserved Shares you want to apply for and the total amount payable in the following appropriate boxes in ink (preferably in black) and mark "X" in the corresponding boxes underneath. 請在以下適當空格內用墨水筆(以黑色為佳)填寫閣下擬申請之超額預留股份數目及應繳總額，並在相應空格內加上「X」。

Number of excess Reserved Shares applied for
申請認購的超額預留股份數目

Total amount of remittance (HK\$)
付款總額(港元)

Grid for entering the number of excess Reserved Shares applied for, with digits 0-9 in individual boxes.

Grid for entering the total amount of remittance (HK\$), with digits 0-9 in individual boxes.

You must pay for the excess Reserved Shares applied for by a separate cheque or banker's cashier order. 閣下必須以獨立開出的支票或銀行本票支付所申請的超額預留股份。

* Cheque or banker's cashier order should be crossed "Account Payee Only" and made payable to "BANK OF CHINA (HONG KONG) NOMINEES LIMITED - WUXI XDC PREFERENTIAL OFFER". The applicant's name/the first applicant's name on the joint application must be the same as the name pre-printed or certified/endorsed by the drawee bank on the cheque/banker's cashier order. * 支票或銀行本票須以「只准入抬頭人賬戶」方式劃線開出，並須註明抬頭人為「中國銀行(香港)代理人有限公司 - 藥明合聯生物技術優先發售」。申請人姓名/名稱/聯名申請排名首位申請人的姓名/名稱須與在支票/銀行本票的預印名稱或付款銀行核證/背面簽署的名稱相同。

Cheque/Banker's cashier order number*
支票/銀行本票號碼*

Signed by (all) applicant(s) (all joint applicants must sign):
由(所有)申請人簽署(所有聯名申請人必須簽署):

Name of bank on which cheque/banker's cashier order is drawn*
支票/銀行本票之付款銀行名稱*

Large empty box for signature of applicant(s).

Contact telephone no.
聯絡電話號碼

You (or, if you are joint applicants, the first-named applicant) must provide your Hong Kong identity card number/passport number/Hong Kong business registration certificate number (Please delete as appropriate)
閣下或(倘閣下為聯名申請人)排名首位申請人必須提供

香港身份證號碼/護照號碼/香港商業登記號碼(請刪除不適用者)

Date 日期: D 日 / M 月 / Y 年

Application Form for Assured Entitlement
保證配額申請表格

For Qualifying WXB Shareholders,
applications will be accepted until 12:00 noon on
Friday, November 10, 2023.

You must read the conditions and
instructions attached to this Application Form.
To be valid, you must complete
all applicable parts of this Application Form.
Please write clearly in English and in ink.

合資格藥明生物技術股東的
截止接受申請時間為

2023年11月10日(星期五)中午十二時正。
閣下務必細閱本申請表格隨附的條件及指示。
本申請表格各適用部分必須以英文用
墨水筆清楚填妥，方為有效。

To: WuXi XDC Cayman Inc.
Joint Sponsors
Overall Coordinators
Joint Global Coordinators
Joint Bookrunners
Joint Lead Managers
Capital Markets Intermediaries
Hong Kong Underwriters

致：藥明合聯生物技術有限公司*
聯席保薦人
整體協調人
聯席全球協調人
聯席賬簿管理人
聯席牽頭經辦人
資本市場中介人
香港包銷商

I/We:

- being the Qualifying WXB Shareholder(s) named overleaf, **apply** for the number of Reserved Shares specified or deemed to be specified, on the terms and conditions of the Prospectus and this Application Form, and subject to the Articles of Association of the Company;
- enclose** payment in full for the Reserved Shares applied for at the Offer Price of HK\$20.60 per Offer Share, plus brokerage of 1%, SFC transaction levy of 0.0027%, the Stock Exchange trading fee of 0.00565% and AFRC Transaction Levy of 0.00015%;
- undertake** and **agree** to accept the Reserved Shares applied for, or any lesser number allotted to me/us on this application;
- warrant** that this is the only application made by me/us for Reserved Shares for my/our own benefit;
- understand** and **confirm** that these declarations and representations will be relied upon by the Company and the Overall Coordinators in deciding whether or not to make any allotment of Reserved Shares to me/us in response to this application and that I/we may be prosecuted for making a false declaration;
- authorize** the Company to place my/our name(s) on the Share Register as the holder(s) of any Reserved Shares to be allotted to me/us and such other registers as required under the Articles of Association of the Company, and dispatch any Share certificate(s) (where applicable) and/or any refund cheque(s) (where applicable) to me/us by ordinary post at my/our own risk to the address stated in this Application Form unless I/we have applied for 1,000,000 Reserved Shares or more and I/we am/are eligible to collect any Share certificate(s) and/or any refund cheque (where applicable) personally, as provided in this Application Form;
- undertake** to sign all documents and to do all things necessary to enable me/us to be registered as the holder of the Reserved Shares to be allocated to me/us, and as required by the Articles of Association of the Company;
- request** that any refund cheque(s) be made payable to me/ the first-named of us (in the case of joint applicants) in this Application Form;

本人/我們:

- 乃名列背頁之合資格藥明生物技術股東，按照招股章程及本申請表格所載條款及條件以及在貴公司組織章程細則之規限下，申請所指定或視作指定數目之預留股份；
- 隨附以發售價每股發售股份20.60港元計算申請認購預留股份所需的全數付款(包括1%經紀佣金、0.0027%證監會交易徵費、0.00565%聯交所交易費及0.00015%會財局交易徵費)；
- 承諾及同意接納本人/我們就本申請所申請認購的預留股份，或獲配發的任何較少數目；
- 保證是項申請乃本人/我們就預留股份為本人/我們本身利益作出之唯一申請；
- 明白及確認貴公司及整體協調人將依賴該等聲明及陳述，以決定是否就本申請向本人/我們配發任何預留股份，而本人/我們如果作出虛假聲明，則可能會被檢控；
- 授權貴公司將本人/我們的姓名/名稱列入股東名冊，作為將配發予本人/我們的任何預留股份的持有人，以及列入貴公司組織章程細則規定的其他登記冊，並按本申請表格上所示地址以普通郵遞方式向本人/我們寄發任何股票(如適用)及/或任何退款支票(如適用)，郵誤風險概由本人/我們自行承擔(除非本人/我們申請1,000,000股或以上預留股份，且本人/我們符合資格按本申請表格規定親身領取任何股票及/或任何退款支票(如適用))；
- 承諾簽署所有文件並進行所有必要的事宜，以及根據貴公司組織章程細則規定讓本人/我們登記為本人/我們獲分配的預留股份的持有人；
- 要求任何退款支票以本人/本申請表格內我們的排名首位者(倘屬聯名申請人)為抬頭人；

- **have** read the terms and conditions and application procedures set out on the pages attached to this Application Form and in the Prospectus and agree to be bound by them, and am aware of the restrictions on the Preferential Offering described in the Prospectus;
 - **represent, warrant and undertake** that the allotment of, or application for, the Reserved Shares would not require the Company, the Joint Sponsors, the Overall Coordinators, the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers, the Capital Markets Intermediaries or the Hong Kong Underwriters to comply with any requirements under any law or regulation (whether or not having the force of law) of any territory outside Hong Kong;
 - **represent, warrant and undertake** that I am not/we are not restricted by any applicable laws of Hong Kong or elsewhere from making this application, paying any application monies for, or being allotted or taking up any Reserved Shares; that I/we understand that the Reserved Shares have not been and will not be registered under the U.S. Securities Act; and that I/we will acquire the Reserved Shares in an “**offshore transaction**” (within the meaning of Regulation S under the U.S. Securities Act); and
 - **agree** that this application, any acceptance of it and the resulting contract, will be governed by and construed in accordance with the laws of Hong Kong.
- 已細閱本申請表格隨附各頁及招股章程所載的條款和條件及申請程序，並同意受其約束且知悉招股章程所述有關優先發售的限制；
 - **聲明、保證及承諾**獲配發或申請認購預留股份不會引致貴公司、聯席保薦人、整體協調人、聯席全球協調人、聯席賬簿管理人、聯席牽頭經辦人、資本市場中介人或香港包銷商須遵從香港以外任何地區的任何法律或法規的任何規定（不論是否具有法律效力）；
 - **聲明、保證及承諾**本人／我們並非香港或其他地區任何適用法律規定不得作出是項申請、支付任何申請款項或獲配發或接納任何預留股份的受限制人士；及本人／我們明白預留股份並無亦將不會根據美國證券法登記，而本人／我們將在「離岸交易」（定義見美國證券法S規例）中購買預留股份；及
 - 同意本申請、任何對本申請的接納以及因此訂立的合約，將受香港法例規管及按其詮釋。

Warning:

- It is important that you read the terms and conditions and application procedures overleaf.
- You must sign this application in writing (and not by way of personal chop), otherwise the application is liable to be rejected.
- Only one application may be made for the benefit of any person for Reserved Shares on a BLUE Application Form. Please refer to the last four bullets of “**D. Effect of completing and submitting this Application Form**” section.
- You may be prosecuted if you make a false declaration.
- All information stated in this Application Form must be the same as that maintained by WuXi Biologics (Cayman) Inc. or any of its wholly-owned subsidiaries.
- **You must complete this application in English in BLOCK letters (except Chinese name) unless otherwise stated, otherwise the application is liable to be rejected.**
- Any alteration to any application detail that you provide on this Application Form should be authorized by the signature of the applicant.
- You or, if you are joint applicants, the first-named applicant must provide your Hong Kong identity card number/passport number/Hong Kong business registration certificate number.

警告：

- 閣下必須細閱背頁的條款和條件及申請程序。
- 閣下必須以書面方式（不得以個人印章方式）簽署本申請，否則申請會被拒絕受理。
- 任何人士只限以藍色申請表格就預留股份作出一次為其利益而進行的認購申請。請參閱「**D. 填交本申請表格的效用**」一節最後四點。
- 倘閣下作出虛假聲明，則可能遭檢控。
- 在本申請表格中聲明的所有資料必須與藥明生物技術有限公司或其任何全資附屬公司所保存者相同。
- 除中文姓名／名稱外，閣下必須以英文正楷填妥本申請（除非另有指明），否則申請會被拒絕受理。
- 閣下於本申請表格提供的任何申請資料如有任何更改，須由申請人簽署授權。
- 閣下或（倘閣下為聯名申請人）排名首位申請人必須提供香港身份證號碼／護照號碼／香港商業登記號碼。

Application Form for Excess Reserved Shares
超額預留股份申請表格

For Qualifying WXB Shareholders,
applications will be accepted until 12:00 noon on
Friday, November 10, 2023.

You must read the conditions and
instructions attached to this Application Form.
To be valid, you must complete
all applicable parts of this Application Form.
Please write clearly in English and in ink.

合資格藥明生物技術股東的
截止接受申請時間為

2023年11月10日(星期五)中午十二時正。
閣下務必細閱本申請表格隨附的條件及指示。
本申請表格各適用部分必須以英文用
墨水筆清楚填妥，方為有效。

To: WuXi XDC Cayman Inc.
Joint Sponsors
Overall Coordinators
Joint Global Coordinators
Joint Bookrunners
Joint Lead Managers
Capital Markets Intermediaries
Hong Kong Underwriters

致：藥明合聯生物技術有限公司*
聯席保薦人
整體協調人
聯席全球協調人
聯席賬簿管理人
聯席牽頭經辦人
資本市場中介人
香港包銷商

I/We:

- being the Qualifying WXB Shareholder(s) named overleaf, **apply** for the number of excess Reserved Shares specified or deemed to be specified, on the terms and conditions of the Prospectus and this Application Form, and subject to the Articles of Association of the Company;
- **enclose** payment in full for the excess Reserved Shares applied for at the Offer Price of HK\$20.60 per Offer Share, plus brokerage of 1%, SFC transaction levy of 0.0027%, the Stock Exchange trading fee of 0.00565% and AFRC Transaction Levy of 0.00015%;
- **undertake** and **agree** to accept the excess Reserved Shares applied for, or any lesser number allotted to me/us on this application;
- **warrant** that this is the only application made by me/us for excess Reserved Shares for my/our own benefit;
- **understand** and **confirm** that these declarations and representations will be relied upon by the Company and the Overall Coordinators in deciding whether or not to make any allotment of excess Reserved Shares to me/us in response to this application and that I/we may be prosecuted for making a false declaration;
- **authorize** the Company to place my/our name(s) on the Share Register as the holder(s) of any excess Reserved Shares to be allotted to me/us and such other registers as required under the Articles of Association of the Company, and dispatch any Share certificate(s) (where applicable) and/or any refund cheque(s) (where applicable) to me/us by ordinary post at my/our own risk to the address stated in this Application Form unless I/we have applied for 1,000,000 excess Reserved Shares or more and I/we am/are eligible to collect any Share certificate(s) and/or any refund cheque (where applicable) personally, as provided in this Application Form;
- **undertake** to sign all documents and to do all things necessary to enable me/us to be registered as the holder of the excess Reserved Shares to be allocated to me/us, and as required by the Articles of Association of the Company;
- **request** that any refund cheque(s) be made payable to me/ the first-named of us (in the case of joint applicants) in this Application Form;
- 乃名列背頁之合資格藥明生物技術股東，按照招股章程及本申請表格所載條款及條件以及在貴公司組織章程細則之規限下，申請所指定或視作指定數目之超額預留股份；
- 隨附以發售價每股發售股份20.60港元計算申請認購超額預留股份所需的全數付款(包括1%經紀佣金、0.0027%證監會交易徵費、0.00565%聯交所交易費及0.00015%會財局交易徵費)；
- 承諾及同意接納本人/我們就本申請所申請認購的超額預留股份，或獲配發的任何較少數目；
- 保證是項申請乃本人/我們就超額預留股份為本人/我們本身利益作出之唯一申請；
- 明白及確認貴公司及整體協調人將依賴該等聲明及陳述，以決定是否就本申請向本人/我們配發任何超額預留股份，而本人/我們如果作出虛假聲明，則可能會被檢控；
- 授權貴公司將本人/我們的姓名/名稱列入股東名冊，作為將配發予本人/我們的任何超額預留股份的持有人，以及列入貴公司組織章程細則規定的其他登記冊，並按本申請表格上所示地址以普通郵遞方式向本人/我們寄發任何股票(如適用)及/或任何退款支票(如適用)，郵誤風險概由本人/我們自行承擔(除非本人/我們申請1,000,000股或以上超額預留股份，且本人/我們符合資格按本申請表格規定親身領取任何股票及/或任何退款支票(如適用))；
- 承諾簽署所有文件並進行所有必要的事宜，以及根據貴公司組織章程細則規定讓本人/我們登記為本人/我們獲分配超額預留股份的持有人；
- 要求任何退款支票以本人/本申請表格內我們的排名首位者(倘屬聯名申請人)為抬頭人；

BLUE Form 藍表 (Excess Application 超額申請)
Please use this Application Form if you are a Qualifying WXB Shareholder
閣下如為合資格藥明生物技術股東，請使用本申請表格

- **have** read the terms and conditions and application procedures set out on the pages attached to this Application Form and in the Prospectus and agree to be bound by them, and am aware of the restrictions on the Preferential Offering described in the Prospectus;
 - **represent, warrant and undertake** that the allotment of, or application for, the excess Reserved Shares would not require the Company, the Joint Sponsors, the Overall Coordinators, the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers, the Capital Markets Intermediaries or the Hong Kong Underwriters to comply with any requirements under any law or regulation (whether or not having the force of law) of any territory outside Hong Kong;
 - **represent, warrant and undertake** that I am not/we are not restricted by any applicable laws of Hong Kong or elsewhere from making this application, paying any application monies for, or being allotted or taking up any excess Reserved Shares; that I/we understand that the excess Reserved Shares have not been and will not be registered under the U.S. Securities Act; and that I/we will acquire the excess Reserved Shares in an “**offshore transaction**” (within the meaning of Regulation S under the U.S. Securities Act); and
 - **agree** that this application, any acceptance of it and the resulting contract, will be governed by and construed in accordance with the laws of Hong Kong.
- 已細閱本申請表格隨附各頁及招股章程所載的條款和條件及申請程序，並同意受其約束且知悉招股章程所述有關優先發售的限制；
 - **聲明、保證及承諾**獲配發或申請認購超額預留股份不會引致貴公司、聯席保薦人、整體協調人、聯席全球協調人、聯席賬簿管理人、聯席牽頭經辦人、資本市場中介人或香港包銷商須遵從香港以外任何地區的任何法律或法規的任何規定（不論是否具法律效力）；
 - **聲明、保證及承諾**本人／我們並非香港或其他地區任何適用法律規定不得作出是項申請、支付任何申請款項或獲配發或接納任何超額預留股份的受限制人士；及本人／我們明白超額預留股份並無亦將不會根據美國證券法登記，而本人／我們將在「離岸交易」（定義見美國證券法S規例）中購買超額預留股份；及
 - **同意**本申請、任何對本申請的接納以及因此訂立的合約，將受香港法例規管及按其詮釋。

Warning:

- It is important that you read the terms and conditions and application procedures overleaf.
- You must sign this application in writing (and not by way of personal chop), otherwise the application is liable to be rejected.
- Only one application may be made for the benefit of any person for Reserved Shares on a BLUE Application Form. Please refer to the last four bullets of “**D. Effect of completing and submitting this Application Form**” section.
- You may be prosecuted if you make a false declaration.
- All information stated in this Application Form must be the same as that maintained by WuXi Biologics (Cayman) Inc. or any of its wholly-owned subsidiaries.
- **You must complete this application in English in BLOCK letters (except Chinese name) unless otherwise stated, otherwise the application is liable to be rejected.**
- Any alteration to any application detail that you provide on this Application Form should be authorized by the signature of the applicant.
- You or, if you are joint applicants, the first-named applicant must provide your Hong Kong identity card number/passport number/Hong Kong business registration certificate number.

警告：

- 閣下必須細閱背頁的條款和條件及申請程序。
- 閣下必須以書面方式（不得以個人印章方式）簽署本申請，否則申請會被拒絕受理。
- 任何人士只限以藍色申請表格就預留股份作出一次為其利益而進行的認購申請。請參閱「**丁.填交本申請表格的效用**」一節最後四點。
- 倘閣下作出虛假聲明，則可能遭檢控。
- 在本申請表格中聲明的所有資料必須與藥明生物技術有限公司或其任何全資附屬公司所保存者相同。
- 除中文姓名／名稱外，閣下必須以英文正楷填妥本申請（除非另有指明），否則申請會被拒絕受理。
- 閣下於本申請表格提供的任何申請資料如有任何更改，須由申請人簽署授權。
- 閣下或（倘閣下為聯名申請人）排名首位申請人必須提供香港身份證號碼／護照號碼／香港商業登記號碼。

BLUE Form 藍表
Please use this Application Form if you are a Qualifying WXB Shareholder
閣下如為合資格藥明生物技術股東，請使用本申請表格

GLOBAL OFFERING OF RESERVED SHARES
to be issued by



WuXi XDC Cayman Inc.
藥明合聯生物技術有限公司*
(Incorporated in the Cayman Islands with limited liability)

GLOBAL OFFERING

Conditions of your Application

Unless otherwise stated, terms used in these conditions have the same meanings ascribed thereto in the Prospectus.

A. Who can apply

1. You and any person(s) for whose benefit you are applying, must be Qualifying WXB Shareholder(s) and must be 18 years of age or older and must have a Hong Kong address.
2. If you are a firm, the application must be in the individual members' names.
3. The number of joint applicants may not exceed four.
4. If you are a body corporate, the application must be signed by a duly authorised officer, who must state his representative capacity, and stamped with your corporation's chop.
5. You must be outside the United States, not be a United States Person (as defined in Regulation S under the U.S. Securities Act) and not be a legal or natural person of the PRC.
6. Unless permitted by the Listing Rules, you cannot apply for any Reserved Shares if you:
 - are an existing beneficial owner of Shares in the Company and/or any of its subsidiaries;
 - are a Director or chief executive of the Company and/or any of the Company's subsidiaries (other than a Director or his associates, who are Qualifying WXB Shareholders who may apply for Reserved Shares pursuant to the Preferential Offering);
 - are a close associate (as defined in the Listing Rules) of any of the above persons; or
 - are a Non-Qualifying WXB Shareholder.

Non-Qualifying WXB Shareholders are:

- (a) WuXi Biologics Shareholders whose names appeared in the register of members of WuXi Biologics on the Record Date and whose addresses as shown in such register in the Specified Territory; and
- (b) Beneficial WuXi Biologics Shareholder(s) at that time who are otherwise known by WuXi Biologics to be resident in the Specified Territory.

Notwithstanding any other provision in the Prospectus or this Application Form, the Company reserves the right to permit any WuXi Biologics Shareholder to take up his/her/its Assured Entitlement to the Reserved Shares if the Company, in its absolute discretion, is satisfied that the transaction in question is exempt from or not subject to the legislation or regulations giving rise to the restrictions described above.

B. Allocation of Reserved Shares

A valid application for a number of Reserved Shares that is less than or equal to your Assured Entitlement will be accepted in full, subject to the terms and conditions set out in this Application Form and assuming that the conditions of the Preferential Offering are satisfied. If an application is made for a number of Reserved Shares that is less than your Assured Entitlement, you MUST apply for a number in one

of the numbers set out in the table of numbers and payments in this Application Form and make a payment of the corresponding amount (other than HKSCC Nominees). If you wish to apply for excess Reserved Shares in addition to your Assured Entitlement, you should complete and sign the BLUE Application Form for excess Reserved Shares and lodge it, together with a separate remittance for the full amount payable on application in respect of the excess Reserved Shares that is greater than your Assured Entitlement, the relevant Assured Entitlement will be satisfied in full, but the excess portion of such application will only be met to the extent that there are sufficient Available Reserved Shares. To the extent that excess applications for the Reserved Shares are:

- (i) less than the Available Reserved Shares, the Available Reserved Shares will first be allocated to satisfy such excess applications for the Reserved Shares in full and thereafter will be allocated, at the discretion of the Overall Coordinators, to the International Offering;
- (ii) equal to the Available Reserved Shares, the Available Reserved Shares will be allocated to satisfy such excess applications for the Reserved Shares in full; or
- (iii) more than the Available Reserved Shares, the Available Reserved Shares will be allocated with an allocation basis which will be consistent with the allocation basis commonly used in the case of over-subscriptions in public offerings in Hong Kong, where a higher allocation percentage will be applied in respect of smaller applications.

If there are any Shares remaining after satisfying the excess applications, such Shares will be re-allocated, at the discretion of the Overall Coordinators, to the International Offering. No preference will be given to any excess applications made to top up odd lot holdings to whole lot holdings of Shares. Nominee companies are regarded as single shareholder for the purpose of this application.

Save for the above, the Preferential Offering will not be subject to the clawback arrangement between the International Offering and the Hong Kong Public Offering. Any application not accompanied by the correct amount of application monies will be treated as invalid in its entirety and no Reserved Shares will be allotted to such applicant.

In addition to any application for Reserved Shares made on a BLUE Application Form, Qualifying WXB Shareholders will be entitled to make one application for Hong Kong Offer Share by giving instructions to HKSCC via CCASS or by applying through the White Form eIPO service under the Hong Kong Public Offering.

Qualifying WXB Shareholders are entitled to apply on the basis of Assured Entitlement of one Reserved Share for every integral multiple of 477 WXB Shares held by each Qualifying WXB Shareholder on the Record Date. Qualifying WXB Shareholders who hold less than 477 WXB Shares on the Record Date will not have an Assured Entitlement to the Reserved Shares, but they will still be entitled to participate in the Preferential Offering by applying for excess Reserved Shares.

C. Supplemental information

If any supplement to the Prospectus is issued, applicants who have already submitted an application will be notified that they are required to confirm their applications. If applicants have been so notified but have not confirmed their applications in accordance with the procedure to be notified, all unconfirmed applications will be deemed revoked.

D. Effect of completing and submitting this Application Form

By completing and submitting this Application Form, you (and if you are joint applicants, each of you jointly and severally) for yourself or as an agent or a nominee on behalf of each person for whom you act:

- **undertake** to execute all relevant documents and **instruct** and **authorise** the Company and/or the Overall Coordinators (or their agents or nominees), as agents of the Company, to execute any documents for you and to do on your behalf all things necessary to register any Reserved Shares allocated to you in your name as required by the Articles of Association;
- **agree** to comply with the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong), the PRC Company Law, the Special Regulations and the Memorandum and Articles of Association of the Company;
- **confirm** that you have read the terms and conditions and application procedures set out in the Prospectus and in this Application Form and agree to be bound by them;
- **confirm** that you have received and read the Prospectus and have only relied on the information and representations contained in the Prospectus in making your application and will not rely on any other information or representations except those in any supplement to the Prospectus;
- **confirm** that you are aware of the restrictions on the Global Offering in the Prospectus;
- **agree** that none of the Company, the Joint Sponsors, the Overall Coordinators, the Joint Global Coordinators, the Underwriters, their respective directors, officers, employees, partners, agents, advisers and any other parties involved in the Global Offering is or will be liable for any information and representations not in the Prospectus (and any supplement to it);
- **agree** to disclose to the Company, our Hong Kong Share Registrar, receiving bank, the Overall Coordinators, the Underwriters and/or their respective advisers and agents any personal data which they may require about you and the person(s) for whose benefit you have made the application;
- if the laws of any place outside Hong Kong apply to your application, **agree** and **warrant** that you have complied with all such laws and none of the Company, the Overall Coordinators and the Underwriters nor any of their respective officers or advisers will breach any law outside Hong Kong as a result of the acceptance of your offer to purchase, or any action arising from your rights and obligations under the terms and conditions contained in the Prospectus and this Application Form;
- **agree** that once your application has been accepted, you may not rescind it because of an innocent misrepresentation;
- **agree** that your application will be governed by the laws of Hong Kong;
- **represent, warrant** and **undertake** that (i) you understand that the Reserved Shares have not been and will not be registered under the U.S. Securities Act; and (ii) you and any person for whose benefit you are applying for the Reserved Shares are outside the United States (as defined in Regulation S) or are a person described in paragraph (h) (3) of Rule 902 of Regulation S;

- **warrant** that the information you have provided is true and accurate;
- **authorise** the Company to place your name(s) on the Company's register of members as the holder(s) of any Reserved Shares allocated to you, and the Company and/or its agents to send any Share certificate(s) and/or any refund cheque(s) to you or the first-named applicant for joint application by ordinary post at your own risk to the address stated on the application, unless you have chosen to collect the Share certificate(s) and/or refund cheque(s) in person;
- **understand** that Company and the Overall Coordinators will rely on your declarations and representations in deciding whether or not to make any allotment of any of the Reserved Shares to you and that you may be prosecuted for making a false declaration;
- **confirm** that you are aware of the restrictions on the Preferential Offering of the Reserved Shares as set out in the Prospectus;
- (if you are an agent for another person) **warrant** that reasonable enquiries have been made of the beneficial owner that this application is the only application which will be made for the benefit of that other person on a **BLUE** Application Form and that you are duly authorised to sign this Application Form as that other person's agent;
- **agree** that once your application is accepted, your application will be evidenced by the results of the Preferential Offering made available by the Company;
- **warrant** that, in making an application, you or any person(s) on whose behalf you may be acting is/are Qualifying WXB Shareholder(s);
- (with the exception of Directors and/or their associates who are Qualifying WXB Shareholders) **represent, warrant** and **undertake** that in making this application, you and/or, with the exception of HKSCC Nominees, any person(s) for whose behalf you may be acting are not connected person(s) or person(s) who will become connected person(s) of the Company immediately upon completion of the Global Offering, the subscription for Reserve Shares by you and/or, with the exception of HKSCC Nominees, any person(s) on whose behalf you may be acting is not financed directly or indirectly by a connected person of the Company, and you and/or, with the exception of HKSCC Nominees, any person(s) on whose behalf you may be acting is not taking instructions from a connected person of the Company in making this subscription for the Reserved Shares;
- **undertake** and **agree** to accept the Reserved Shares applied for, or any lesser number allocated to you under the application;
- **agree** with the Company and for itself and for the benefit of each holder of the Reserved Shares (and so that the Company shall be deemed by their acceptance in whole or in part of this application to have agreed, for itself and on behalf of each holder of Reserved Shares) (and if applicable, with each CCASS Participant giving **electronic application instructions**), and the Company agree with each holder of the Reserved Shares, to observe and comply with Companies (Winding Up and Miscellaneous Provisions) Ordinance and the Articles of Association of the Company;

The Company, the Overall Coordinators and the Underwriters and any of their respective officers or advisers are entitled to rely on any warranty, representation or declaration made by you in this application with the exception of HKSCC Nominees. In the event of the application being made by joint applicants, all the warranties, representations, declarations and obligations expressed to be made, given or assumed by or imposed on the joint applicants shall be deemed to have been made, given and assumed by and imposed on the applicants jointly and severally. You may be prosecuted if you make a false declaration.

You must complete this application in English, unless otherwise stated, and you or (in case of joint applicants) each of the joint applicants must sign this application in writing (and not by way of personal chop), otherwise the application is liable to be rejected.

E. Power of attorney

If your application is made through an authorised attorney, the Company and the Overall Coordinators may accept or reject your application at their discretion, and on any conditions they think fit, including evidence of the attorney's authority. The Company and the Overall Coordinators, as the Company's agents, will have full discretion to reject or accept any application, in full or in part without giving any reason.

F. Offer Price

Applicants are required to pay the Offer Price of HK\$20.60 for each Reserved Share together with 1% brokerage, 0.0027% SFC transaction levy, 0.00565% the Stock Exchange trading fee and 0.00015% AFRC Transaction Levy.

Allotment of Reserved Shares

Subject to the terms and conditions as set out herein and in the Prospectus, the Reserved Shares will be allotted after the application lists close. The level of applications in the Hong Kong Public Offering and the Preferential Offering, the level of indications of interest in the International Offering and the basis of allocations of the Reserved Shares are also expected to be announced on Thursday, November 16, 2023 in both cases on the websites of the Company at www.wuxidc.com and the Stock Exchange at www.hkexnews.hk. Results of allocations of the Preferential Offering, and the Hong Kong identity card/passport/Hong Kong business registration numbers of successful applicants (where appropriate) will be made available on Thursday, November 16, 2023 through various channels as described in the section headed "How to Apply for Hong Kong Offer Shares and Reserved Shares – F. Publication of Results" in the Prospectus.

If your application for Reserved Shares is successful (in whole or in part)

If you apply for 1,000,000 or more Reserved Shares, you may collect refund cheque(s) and/or Share certificate(s) in person from: Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong from 9:00 a.m. to 1:00 p.m. on Thursday, November 16, 2023 or such other date as notified the Company by announcement on such even date.

If you are an individual who is eligible for personal collection, you must not authorise any other person to collect for you. If you are a corporate applicant which is eligible for personal collection, your authorised representative must bear a letter of authorisation from your corporation stamped with your corporation's chop. Both individuals and authorised representatives must produce, at the time of collection, evidence of identity acceptable to Computershare Hong Kong Investor Services Limited.

If you do not collect your refund cheques and/or Share certificate(s) personally within the time period specified for collection, they will be dispatched promptly to the address as specified on this Application Form by ordinary post at your own risk.

If you apply for less than 1,000,000 Reserved Shares, your refund cheque(s) and/or Share certificate(s) will be sent to the address on the relevant Application Form on or before Thursday, November 16, 2023, by ordinary post and at your own risk.

The Company will not issue temporary documents of title.

Share certificates will only become valid at 8:00 a.m. on Friday, November 17, 2023 provided that the Global Offering has become unconditional and the right of termination described in the section headed "Underwriting" in the Prospectus has not been exercised. No receipt will be issued for sums paid on application. Investors who trade Shares prior to the receipt of Share certificates or the Share certificates becoming valid do so at their own risk.

Circumstances in which you will not be allotted Reserved Shares

You may not be allocated Reserved Shares for any of the following reasons:

1. If your application is revoked:

By completing and submitting an Application Form or giving **electronic application instructions** to HKSCC, you agree that your application or the application made by HKSCC Nominees on your behalf cannot be revoked on or before the expiration of the fifth day after the time of the opening of the application lists (excluding for this purpose any day which is Saturday, Sunday or public holiday in Hong Kong), unless a person responsible for the Prospectus under Section 40 of the Companies (Winding Up and Miscellaneous Provisions) Ordinance gives a public notice under that section which excludes or limits the responsibility of that person for the Prospectus. This agreement will take effect as a collateral contract with the Company, and will become binding when you lodge this Application Form. This collateral contract will be in consideration of the Company agreeing that it will not offer any Reserved Shares to any person on or before Thursday, November 16, 2023, except by means of one of the procedures referred to in the Prospectus.

If your application has been accepted, it cannot be revoked. For this purpose, acceptance of applications which are not rejected will be constituted by notification in the announcement of the results of allocation, and where such basis of allocation is subject to certain conditions or provides for allocation by ballot, such acceptance will be subject to the satisfaction of such conditions or results of the ballot, respectively.

2. Full discretion of the Company, the Overall Coordinators, and their respective agents or nominees, to reject or accept your application:

The Company and the Overall Coordinators or its or their respective agents or nominees, have full discretion to reject or accept any application, or to accept only part of any application.

No reasons have to be given for any rejection or acceptance.

3. If the allotment of Reserved Shares is void:

The allotment of Reserved Shares to you will be void if the Listing Committee does not grant permission to list the Offer Shares either:

- within three weeks from the closing of the application lists; or
- within a longer period of up to six weeks if the Listing Committee notifies the Company of that longer period within three weeks of the closing date of the application lists.

4. You will not receive any allotment if:

- this Application Form is not completed in accordance with the instructions as stated herein;
- this Application Form has not been duly signed (only written signatures are acceptable) (or in the case of a joint application, not all applicants have signed);

BLUE Form 藍表

Please use this Application Form if you are a Qualifying WXB Shareholder

閣下如為合資格藥明生物技術股東，請使用本申請表格

- in respect of applicants who are corporate entities, this Application Form has not been duly signed (only written signature is acceptable) by an authorised officer or affixed with a company chop;
 - the cheque/banker's cashier order/this Application Form is defective;
 - this Application Form is not accompanied with a cheque/banker's cashier order or is accompanied by more than one cheque/banker's cashier order for each of the application for Assured Entitlement and excess application for Reserved Shares;
 - the account name on cheque/banker's cashier order is not pre-printed or certified by the issuing bank;
 - the cheque/banker's cashier order is not drawn on a Hong Kong dollar bank account in Hong Kong;
 - the name of the payee indicated on the cheque/banker's cashier order is not "BANK OF CHINA (HONG KONG) NOMINEES LIMITED – WUXI XDC PREFERENTIAL OFFER";
 - the cheque has not been crossed "Account payee only";
 - the cheque was post-dated;
 - the applicant's payment is not made correctly or the applicant pays by cheque or banker's cashier order and the cheque or banker's cashier order is dishonoured on its first presentation;
 - the applicant's name/the first applicant's name on the joint application is not the same as the name pre-printed or certified/endorsed by the drawee bank on the cheque/banker's cashier order;
 - alteration(s) to the application details on this Application Form has not been authorised by the signature(s) of the applicant(s);
 - the Company believe that by accepting the application, the Company would violate the applicable securities or other laws, rules or regulations of the jurisdiction where this Application Form is received or where the applicant's address is located; or
 - the Company and the Overall Coordinators, and their respective agents or nominees, exercise their discretion to reject or accept any application, or to accept only part of any application. No reasons have to be given for any rejection or acceptance.
5. If you are applying by using the **BLUE** Application Form for Assured Entitlement, you may apply for a number of Reserved Shares pursuant to your Assured Entitlement that is equal to or less than the number stated in Box B. If you intend to apply for a number of Reserved Shares that is less than your Assured Entitlement, you **MUST** apply for a number which is one of the numbers set out in the table in the **BLUE** Application Form and make a payment of the corresponding amount (other than HKSCC Nominees). You need to complete and sign the **BLUE** Application Form for Assured Entitlement and submit one cheque (or banker's cashier order) for the exact amount of remittance printed in Box B or the corresponding amount payable as set out in the table in the **BLUE** Application Form. If you wish

to apply for excess Reserved Shares in addition to your Assured Entitlement, you should complete and sign the **BLUE** Application Form for excess Reserved Shares and lodge it, together with a separate remittance for the full amount payable on application in respect of the excess Reserved Shares applied for.

6. If you are applying by using the **BLUE** Application Form for excess Reserved Shares, you **MUST** apply for a number which is one of the numbers set out in the table in the **BLUE** Application Form for excess Reserved Shares and make a payment of the corresponding amount (other than HKSCC Nominees). You need to complete and sign the **BLUE** Application Form for excess Reserved Shares and submit a separate cheque (or banker's cashier order) for the exact amount of remittance.
7. If you intend to apply for both Reserved Shares pursuant to your Assured Entitlement and excess Reserved Shares, you must submit both the **BLUE** Application Form for Assured Entitlement and the **BLUE** Application Form for excess Reserved Shares. Each **BLUE** Application Form must be accompanied by a separate cheque (or banker's cashier order) for the exact amount of remittance.

Refund of your money

If you do not receive any Reserved Shares or if your application is accepted only in part, the Company will refund to you your application monies (including the related 1% brokerage, 0.0027% SFC transaction levy, 0.00565% the Stock Exchange trading fee and 0.00015% AFRC Transaction Levy) or the appropriate portion thereof without interest. The refund procedures are stated in the "I. Dispatch/Collection of Share Certificates/e-Refund Payment Instructions/Refund Cheques" in the "How to Apply for Hong Kong Offer Shares and Reserved Shares" section of the Prospectus.

Effect of the Information You Give to Computershare Hong Kong Investor Services Limited

Computershare Hong Kong Investor Services Limited and its related bodies' corporate, directors, officers, employees and agents ("**Representatives**") expressly disclaim and exclude to the maximum extent permitted by law any liability for any loss or damage suffered or incurred by the applicant or any other person or entity however caused relating in any way to, or connected with, any information provided by or on behalf of the applicant on or in connection with this document or any services provided hereunder, or any other written or oral communication provided by or on behalf of the applicant in connection with this document or any services provided hereunder. This includes, without limitation, any errors or omissions in such information however caused, or the Representatives or any other person or entity placing any reliance on such information or any documentation, image, recording or reproduction of such information, or its accuracy, completeness, currency or reliability.

By signing this Application Form, you agree to all of the above.

How to make your application

1. **If you are applying by using the BLUE Application Form for Assured Entitlement**, you may apply for a number of Reserved Shares pursuant to your Assured Entitlement that is equal to or less than the number stated in Box B in the Application Form. If you intend to apply for a number of Reserved Shares that is less than your Assured Entitlement, you **MUST** apply for a number which is one of

the numbers set out in the table in the **BLUE** Application Form for Assured Entitlement, you should (i) write the number of Reserved Shares applied for and the amount payable (as set out in the table in the Application Form); (ii) complete and sign the Application Form; and (iii) submit one cheque (or banker's cashier order) for the same amount that you have written in the Application Form (other than HKSCC Nominees).

BLUE Form 藍表

Please use this Application Form if you are a Qualifying WXB Shareholder

閣下如為合資格藥明生物技術股東，請使用本申請表格

If you wish to apply for excess Reserved Shares in addition to your Assured Entitlement, you should complete and sign the BLUE Application Form for excess Reserved Shares and lodge it, together with a separate remittance for the full amount payable on application in respect of the excess Reserved Shares applied for. If you intend to apply for a number of Reserved Shares that is equal to your Assured Entitlement, you should (i) complete and sign the Application Form and (ii) submit one cheque (or banker's cashier order) for the exact amount of remittance printed in Box B in the Application Form.

If you are applying by using the BLUE Application Form for excess Reserved Shares, you should (i) write the number of excess Reserved Shares applied for and the amount payable (as set out in the table on the Application Form); (ii) complete and sign the Application Form; and (iii) submit one separate cheque (or banker's cashier order) for the same amount that you have written on the Application Form. The number of excess Reserved Shares that you intend to apply for MUST be one of the numbers set out in the table in the Application Form (other than HKSCC Nominees). If the number of excess Reserved Shares applied for is not one of the numbers set out in the table in the Application Form, the excess application is liable to be rejected.

2. The amount of the remittance payable on application will be equal to the number of Reserved Shares applied for multiplied by the Offer Price of HK\$20.60 per Offer Share plus brokerage of 1%, SFC transaction levy of 0.0027%, the Stock Exchange trading fee of 0.00565% and AFRC Transaction Levy of 0.00015%. For your easy reference, the table in this Application Form sets out the amount of remittance payable for applications in certain numbers of Reserved Shares.

It should be noted that Assured Entitlement may represent shares not in whole multiples of a full board lot of 500 shares. There is no guarantee that your resultant aggregate holding of shares will form an integral multiple of 500 shares.

3. Complete the form and sign it. **Only written signatures will be accepted.**
4. Staple your cheque or bank's cashier order to the form. You must pay for the Reserved Shares applied for by one cheque or by one banker's cashier order. Each application must be accompanied by either a separate cheque or banker's cashier order.

If you pay by cheque, the cheque must:

- be in Hong Kong dollars;
- be drawn on your Hong Kong dollar bank account in Hong Kong;
- show your account name. This name must either be pre-printed on the cheque, or be endorsed at the back by a person authorised by the bank. This account name must be the same name as the name on this form. If it is a joint application, the account name must be the same as the name of the first-named applicant;
- be made payable to "BANK OF CHINA (HONG KONG) NOMINEES LIMITED – WUXI XDC PREFERENTIAL OFFER";
- be crossed "Account Payee Only"; and
- not be post-dated.

Your application may be rejected if your cheque:

- does not meet all these requirements; or
- is dishonoured on its first presentation.

If you pay by banker's cashier order, the cashier order must:

- be in Hong Kong dollars;
- be issued by licensed banks in Hong Kong, and have your name certified at the back of the order by a person authorised by the bank. The name on the back of the order and the name on this Application Form must be the same. If it is a joint application, the name at the back of the order must be the same as the name of the first-named applicant;

- be made payable to "BANK OF CHINA (HONG KONG) NOMINEES LIMITED – WUXI XDC PREFERENTIAL OFFER";
- be crossed "Account Payee Only"; and
- not be post-dated.

Your application is liable to be rejected if your cheque or banker's cashier order does not meet all these requirements.

5. Fold this Application Form once and lodge it in the special collection box at Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong.
6. This Application Form can be lodged at these times:
- Tuesday, November 7, 2023 – 9:00 a.m. to 4:30 p.m.
 - Wednesday, November 8, 2023 – 9:00 a.m. to 4:30 p.m.
 - Thursday, November 9, 2023 – 9:00 a.m. to 4:30 p.m.
 - Friday, November 10, 2023 – 9:00 a.m. to 12:00 noon
7. The latest time for lodging your application is 12:00 noon on Friday, November 10, 2023 or, if the application lists are not open on that day, then by 12:00 noon on the next day the lists are open. The application lists will be open between 11:45 a.m. and 12:00 noon on that day, subject only to weather conditions. The application lists will not open if there is:
- a tropical cyclone warning signal 8 or above, or
 - a "black" rainstorm warning, and/or
 - Extreme Conditions,
- in force in Hong Kong at any time between 9:00 a.m. and 12:00 noon on Friday, November 10, 2023. Instead they will be open between 11:45 a.m. and 12:00 noon on the next business day which does not have either of those warnings in Hong Kong in force at any time between 9:00 a.m. and 12:00 noon. Business day means a day that is not a Saturday, Sunday or public holiday in Hong Kong.
8. **The right is reserved to present all or any remittances for payment. However, your cheque or banker's cashier order will not be presented for payment before 12:00 noon on Friday, November 10, 2023. You will not be given a receipt for your payment. The Company will retain any interest accrued on your application monies. The right is also reserved to retain any Share certificate(s) and/or any surplus application money(ies) or refunds pending clearance of your cheque or banker's cashier order.**

BLUE Form 藍表
Please use this Application Form if you are a Qualifying WXB Shareholder
閣下如為合資格藥明生物技術股東，請使用本申請表格

全球發售
由本公司發行的預留股份



WuXi XDC Cayman Inc.
藥明合聯生物技術有限公司*
(於開曼群島註冊成立的有限公司)

全球發售

申請條件

除另有指明外，此等條件所用詞彙具備招股章程所賦予的相同涵義。

甲. 可提出申請的人士

- 閣下及閣下為其利益提出申請的人士必須為合資格藥明生物技術股東及年滿18歲並有香港地址。
- 如閣下為商號，申請須以個別成員名義提出。
- 聯名申請人不得超過四名。
- 如閣下為法人團體，申請須經獲正式授權人員簽署，並註明其所屬代表身份及蓋上公司印章。
- 閣下必須身處美國境外，並非美籍人士（定義見美國證券法S規例），亦非中國法人或自然人。
- 除上市規則批准外，下列人士概不得申請認購任何預留股份：
 - 本公司及／或其任何附屬公司股份的現有實益擁有人；
 - 本公司及／或本公司的任何附屬公司的董事或最高行政人員（身為可根據優先發售申請預留股份的合資格藥明生物技術股東的董事或其聯繫人除外）；
 - 上述任何人士的緊密聯繫人（定義見上市規則）；或
 - 不合資格藥明生物技術股東。

不合資格藥明生物技術股東為：

- 於記錄日期名列藥明生物技術股東名冊且在該名冊內所示地址位於特定地區的藥明生物技術股東；及
- 當時藥明生物技術另行得悉為特定地區居民的實益藥明生物技術股東。

儘管招股章程或本申請表格中有任何其他規定，倘本公司全權酌情信納有關交易獲豁免或不受制於上述限制的法律或法規的約束，本公司保留權利批准任何藥明生物技術股東享有其預留股份的保證配額。

乙. 分配預留股份

倘有效申請之預留股份數目少於或相等於閣下之保證配額，在受本申請表格所載條款及條件的規限下，且假設優先發售之條件已達成，則申請將會獲全數接納。倘申請的預留股份數目少於閣下的保證配額，閣下必須申請本申請表格內數目及款項一

覽表所列的其中一個數目並支付相應款額（香港結算代理人除外）。倘閣下擬申請保證配額以外的超額預留股份，則須交回經填妥並簽署的申請超額預留股份之藍色申請表格，並單獨匯款足額支付所申請超額預留股份的應付股款。倘申請的預留股份數目多於閣下的保證配額，相關的保證配額將獲全數接納，但上述申請的超額部分則只有在有足夠的可用預留股份的情況下方獲接納。倘預留股份的超額申請：

- 少於可用預留股份，則可用預留股份將首先悉數分配以滿足該等預留股份的超額申請，而其後將由整體協調人酌情分配至國際發售；
- 與可用預留股份相同，則可用預留股份將悉數分配以滿足該等預留股份的超額申請；或
- 多於可用預留股份，則可用預留股份將按與香港公開發售超額認購情況下常用的分配基準一致的分配基準分配，當中認購額較細的申請將獲較高的分配百分比。

倘滿足超額申請後剩餘任何股份，有關股份將由整體協調人酌情重新分配至國際發售。為補足股份的零碎持有量至一手完整持有量而作出的任何超額申請將不會獲得優先處理。就此申請而言，代理人公司視為單一股東。

除上述者外，優先發售將不受國際發售與香港公開發售之間的回撥安排所限。未附上正確申請款項金額的任何申請將被視為全部無效，而該申請人將不會獲配發任何預留股份。

除以藍色申請表格申請預留股份外，合資格藥明生物技術股東將有權根據香港公開發售通過中央結算系統向香港結算發出申請指示或通過白表eIPO服務作出一份香港發售股份申請。

合資格藥明生物技術股東有權按每名合資格藥明生物技術股東於記錄日期每持有477股藥明生物技術股份的完整倍數可獲一股預留股份的保證配額基準提出申請。於記錄日期持有少於477股藥明生物技術股份的合資格藥明生物技術股東將無預留股份的保證配額，惟彼等仍將有權通過申請超額預留股份參與優先發售。

BLUE Form 藍表

Please use this Application Form if you are a Qualifying WXB Shareholder

閣下如為合資格藥明生物技術股東，請使用本申請表格

丙. 補充資料

倘發出招股章程的任何補充文件，已遞交申請的申請人將會獲通知須確認其申請。倘申請人接獲通知但卻並無根據所獲通知的流程確認其申請，所有未確認的申請一概視作撤回。

丁. 填交本申請表格的效用

閣下填妥並遞交本申請表格，即表示閣下（如屬聯名申請人，即各人共同及個別）代表閣下本身，或作為閣下代其行事的每位人士之代理或代名人：

- 承諾簽立所有相關文件，並指示及授權本公司及／或作為本公司代理的整體協調人（或彼等的代理或代名人），代表閣下簽立任何文件，並為按照組織章程細則的規定將閣下獲分配的任何預留股份以閣下名義登記而代表閣下採取一切所需行動；
- 同意遵守香港法例第622章公司條例、香港法例第32章公司（清盤及雜項條文）條例、中國公司法、特別規定以及本公司的組織章程大綱及章程細則；
- 確認閣下已細閱招股章程及本申請表格所載的條款及條件以及申請程序，並同意受其約束；
- 確認閣下已接獲及細閱招股章程，提出申請時也僅依據招股章程載列的資料及陳述，而除招股章程任何補充文件外，不會依賴任何其他資料或陳述；
- 確認閣下知悉招股章程內有關全球發售的限制；
- 同意本公司、聯席保薦人、整體協調人、聯席全球協調人、包銷商、彼等各自的董事、高級人員、僱員、合夥人、代理、顧問及參與全球發售的任何其他各方現時及日後均毋須對並非載於招股章程（及其任何補充文件）的任何資料及陳述負責；
- 同意在本公司、香港證券登記處、收款銀行、整體協調人、包銷商及／或彼等各自的顧問及代理提出要求時，向彼等披露其所要求有關閣下及閣下為其利益提出申請的人士的任何個人資料；
- 若如香港境外任何地方的法律適用於閣下的申請，則同意及保證閣下已遵守所有有關法律，且本公司、整體協調人及包銷商和彼等各自的高級人員或顧問概不會因接納閣下的購買要約，或閣下在招股章程及本申請表格所載的條款及條件項下的權利及責任所引致的任何行動，而違反香港境外的任何法律；
- 同意閣下的申請一經接納，即不得因無意的失實陳述而撤銷；
- 同意閣下的申請受香港法例規管；
- 聲明、保證及承諾：(i)閣下明白預留股份不曾亦不會根據美國證券法登記；及(ii)閣下及閣下為其利益申請預留股份的任何人士均身處美國境外（定義見S規例），或屬S規例第902條第(h)(3)段所述的人士；

- 保證閣下提供的資料真實及準確；
 - 授權本公司將閣下的姓名／名稱列入本公司股東名冊，作為閣下獲分配的任何預留股份的持有人，並授權本公司及／或其代理以普通郵遞方式按申請所示地址向閣下或聯名申請的排名首位申請人發送任何股票及／或退款支票，郵誤風險由閣下承擔，除非閣下已選擇親身領取股票及／或退款支票；
 - 明白本公司及整體協調人將依據閣下的聲明及陳述而決定是否向閣下分配任何預留股份，閣下如作出虛假聲明，可能會被檢控；
 - 確認閣下知悉招股章程所述有關預留股份的優先發售限制；
 - （如閣下為他人的代理）保證已向實益擁有人作出合理查詢，證實本申請乃為該人士利益以藍色申請表格而作出的唯一申請，而閣下已獲正式授權，以該人士代理的身份簽署本申請表格；
 - 同意一旦閣下的申請獲接納，閣下的申請將以本公司發出的優先發售結果為證；
 - 保證在提出申請時，閣下或閣下可能代其行事之任何人士為合資格藥明生物技術股東；
 - （身為合資格藥明生物技術股東的董事及／或彼等的聯繫人除外）聲明、保證及承諾，在提出本申請時，閣下及／或閣下可能代其行事之任何人士（香港結算代理人除外）並非關連人士，亦並非將在緊隨全球發售完成後成為本公司關連人士的人士，而閣下及／或閣下可能代其行事之任何人士（香港結算代理人除外）認購預留股份並非直接或間接由本公司的關連人士提供資金，且閣下及／或閣下可能代其行事之任何人士（香港結算代理人除外）並非根據本公司關連人士的指示作出是次預留股份認購；
 - 承諾並同意接納所申請的預留股份，或閣下根據申請所獲分配的任何較少數目；
 - 向本公司（為其本身及代表各預留股份持有人利益）表示同意（因此本公司（為其本身並代表各預留股份持有人）藉其接納全部或部分本申請而被視為已同意）（及（如適用）向發出電子認購指示的各中央結算系統參與者表示同意），以及本公司向各預留股份持有人表示同意，遵守及符合公司（清盤及雜項條文）條例及本公司組織章程細則；
- 除香港結算代理人外，本公司、整體協調人、包銷商及彼等各自的任何高級人員或顧問均有權依賴閣下在本申請中作出的任何保證、陳述或聲明。如為聯名申請人提出申請，聯名申請人明確作出、提供、承擔或被施加的所有保證、陳述、聲明及責任將視為由申請人共同及個別地作出、提供、承擔及被施加。閣下如作出虛假聲明，可能會遭檢控。

BLUE Form 藍表
Please use this Application Form if you are a Qualifying WXB Shareholder
閣下如為合資格藥明生物技術股東，請使用本申請表格

除非另有訂明，否則閣下必須以英文填妥本申請，且閣下或（如為聯名申請人）各聯名申請人必須親筆簽署本申請（不得以個人印章代替），否則申請可被拒絕受理。

戊. 授權書

如閣下通過授權人士提出申請，本公司及整體協調人可按其認為合適的條件（包括出示獲授權證明）酌情接納或拒絕閣下的申請。本公司及作為本公司代理的整體協調人將可全權酌情拒絕或接納任何申請的全部或部分，而毋須申述任何理由。

己. 發售價

申請人須繳付每股預留股份20.60港元的發售價，另加1%經紀佣金、0.0027%證監會交易徵費、0.00565%聯交所交易費及0.00015%會財局交易徵費。

預留股份的配發

在本申請表格及招股章程載列的條款及條件規限下，預留股份將於截止辦理申請登記後配發。香港公開發售及優先發售的申請水平、國際發售的踴躍程度及預留股份的分配基準預期亦將於2023年11月16日（星期四）公佈，兩者均在本公司網站 www.wuxidc.com 及聯交所網站 www.hkexnews.hk 刊登。優先發售的分配結果，以及成功申請人的香港身份證／護照／香港商業登記號碼（如適用），將於2023年11月16日（星期四）通過於招股章程「如何申請香港發售股份及預留股份—F. 公佈結果」一節所述的多個渠道公佈。

如閣下成功申請認購預留股份（全部或部分）

如閣下申請認購1,000,000股或以上預留股份，閣下可於2023年11月16日（星期四）上午九時正至下午一時正或本公司於該日公佈的其他日期，親身前往香港中央證券登記有限公司（地址為香港灣仔皇后大道東183號合和中心17樓1712-1716號舖）領取退款支票及／或股票。

如閣下為個人申請人並合資格親身領取，閣下不得授權任何其他人士代領。如閣下為公司申請人並合資格派人領取，閣下的授權代表須攜同蓋上公司印章的授權書領取。個人申請人及授權代表領取股票時均須出示香港中央證券登記有限公司接納的身份證明文件。

如閣下並無在指定領取時間內親身領取退款支票及／或股票，有關退款支票及／或股票將會立刻以普通郵寄方式寄往本申請表格所示地址，郵誤風險由閣下承擔。

如閣下申請認購1,000,000股以下預留股份，閣下的退款支票及／或股票將於2023年11月16日（星期四）或之前以普通郵遞方式寄往相關申請表格所示地址，郵誤風險由閣下承擔。

本公司不會發出臨時所有權文件。

股票將僅在全球發售已成為無條件以及招股章程「包銷」一節所述終止權利未獲行使的情況下，方會於2023年11月17日（星期五）上午八時正成為有效證書。本公司不會就申請時支付的款項發出收據。投資者如在獲發股票前或股票成為有效證書前買賣股份，須自行承擔一切風險。

閣下不獲配發預留股份的情況

閣下可能基於下列任何理由而不獲分配預留股份：

1. 倘閣下的申請被撤回：

填妥及遞交申請表格或向香港結算發出電子認購指示，即表示閣下同意不得於開始辦理申請登記時間後第五日（就此而言，不包括星期六、星期日或香港公眾假期的任何日子）屆滿或之前撤回申請或香港結算代理人代表閣下提出的申請，除非根據公司（清盤及雜項條文）條例第40條對招股章程負責的人士根據該條發出公告，免除或限制該人士對招股章程的責任。此協議將成為與本公司訂立的附屬合約，並在閣下遞交本申請表格時即具約束力。該附屬合約的對價為本公司同意，除按招股章程所述任何一項程序外，不會於2023年11月16日（星期四）或之前向任何人士提早發售任何預留股份。

閣下的申請一經接納，則不得撤回。就此而言，公佈分配結果即屬接納未遭拒絕的申請，而倘有關分配基準受若干條件規限或訂定以抽籤方式分配，則申請獲接納與否將分別視乎能否達成有關條件或抽籤的結果而定。

2. 本公司、整體協調人以及彼等各自的代理或代名人可全權酌情決定拒絕或接納閣下的申請：

本公司及整體協調人或其或彼等各自的代理或代名人可全權酌情決定拒絕或接納任何申請，或僅接納任何部分申請。

彼等毋須就任何拒絕或接納提供任何理由。

3. 倘預留股份配發作廢：

倘上市委員會在下列期間未批准發售股份上市，則配發予閣下的預留股份將告作廢：

- 由截止辦理申請登記日期起計三星期內；或
- （倘上市委員會在截止辦理申請登記日期後三星期內通知本公司延長有關期間）由截止辦理申請登記日期起計最多六星期內。

4. 在下列情況下，閣下將不獲任何配發：

- 本申請表格並無按照本申請表格所載指示填妥；
- 本申請表格並無妥為簽署（僅接受親筆簽名）（或倘為聯名申請，則未經全部申請人簽署）；

BLUE Form 藍表

Please use this Application Form if you are a Qualifying WXB Shareholder

閣下如為合資格藥明生物技術股東，請使用本申請表格

- 就法人團體申請人而言，本申請表格未經獲授權的高級人員妥為簽署（僅接受親筆簽名）或未加蓋公司印章；
 - 支票／銀行本票／本申請表格有缺陷；
 - 本申請表格並無就各份保證配額的申請及預留股份的超額申請附有支票／銀行本票或附有超過一張支票／銀行本票；
 - 支票／銀行本票並無預印賬戶名稱或賬戶名稱未經開具銀行證明；
 - 支票／銀行本票並非自香港的港元銀行賬戶開出；
 - 支票／銀行本票的抬頭人並非「中國銀行（香港）代理人有限公司－藥明合聯生物技術優先發售」；
 - 支票並無劃線註明「只准入抬頭人賬戶」；
 - 支票為期票；
 - 申請人未正確付款或申請人以支票或銀行本票付款但支票或銀行本票於首次過戶時不獲兌現；
 - 申請人姓名／名稱／聯名申請排名首位申請人的姓名／名稱並非預印名稱或付款銀行在支票／銀行本票核證／背面簽署的名稱；
 - 本申請表格所提供申請資料的更改未獲申請人簽署授權；
 - 本公司認為如接納申請，會違反收取本申請表格或申請人地址所在司法管轄區的適用證券或其他法律、規則或法規；或
 - 本公司及整體協調人以及彼等各自的代理或代名人酌情拒絕或接納任何申請，或僅接納申請其中一部分，毋須就拒絕或接納給予理由。
5. 倘閣下使用藍色申請表格申請保證配額，閣下可根據保證配額申請相等於或少於乙欄所列數目的預留股份數目。倘閣下擬申請少於閣下的保證配額的預留股份數目，閣下必須申請藍色申請表格列表所列的其中一個數目，並相應付款（香港結算代理人除外）。閣下需就保證配額填妥並簽署藍色申請表格，並提交一張支票（或銀行本票），金額須為乙欄所印列的確定匯款金額或藍色申請表格列表所載的相應應付金額。倘閣下擬申請保證配

額以外的超額預留股份，則須交回經填妥並簽署的申請超額預留股份之藍色申請表格，並單獨匯款足額支付所申請超額預留股份的應付股款。

6. 倘閣下使用藍色申請表格申請超額預留股份，閣下必須申請藍色申請表格列表所列超額預留股份數目其中之一，並相應付款（香港結算代理人除外）。閣下需就超額預留股份填妥並簽署藍色申請表格，並提交一張獨立開出並填寫確切匯款金額的支票（或銀行本票）。
7. 倘閣下擬同時申請保證配額項下的預留股份以及超額預留股份，閣下必須同時提交保證配額的藍色申請表格及超額預留股份的藍色申請表格。每份藍色申請表格必須附上一張獨立開出並填寫確切匯款金額的支票（或銀行本票）。

退回款項

若閣下未獲分配任何預留股份或申請僅部分獲接納，本公司將不計利息退回閣下的申請股款或其中適當部分（包括相關的1%經紀佣金、0.0027%證監會交易徵費、0.00565%聯交所交易費及0.00015%會財局交易徵費）。有關退款程序載於招股章程「如何申請香港發售股份及預留股份」一節「I. 寄發／領取股票／電子退款指示／退款支票」。

閣下提供給香港中央證券登記有限公司的資料的有關影響

香港中央證券登記有限公司和其有關連的法人團體、董事、高級人員、僱員及代理（「代表」）在法律所容許的最大限度內明確卸棄及免除在任何方面與申請人或代表申請人在此文件提供的或與此文件或在此文件下提供的任何服務相關的任何資料，或任何申請人或代表申請人提供與此文件或在此文件下提供的任何服務相關的任何其他書面或口頭通訊，有關或相關由申請人或任何其他人士或實體所遭受或招致不論如何造成的任何損失或損害的任何法律責任。此包括但不限於該等資料中不論如何造成的任何錯誤或遺漏，或代表或任何其他人士或實體對該等資料或任何該等資料的文件記錄、影像、記錄或複製品作出的任何依賴，或其準確性、完整性、合時性或可靠性。

如閣下簽署本申請表格，即表示閣下同意上述各項。

申請程序

1. 倘閣下使用藍色申請表格申請保證配額，閣下可根據保證配額申請相等於或少於申請表格乙欄所列數目的預留股份數目。倘閣下擬申請少於閣下的保證配額的預留股份數目，閣下必須申請藍色申請表格申請保證配額表中載列的其中一個預留股份數

目，閣下應：(i) 填寫所申請的預留股份數目及應支付的金額（誠如申請表格列表所載者）；(ii) 填寫並簽署申請表格；及(iii) 提交一張支票（或銀行本票），金額須為閣下在申請表格填寫的相同金額（香港結算代理人除外）。

BLUE Form 藍表

Please use this Application Form if you are a Qualifying WXB Shareholder

閣下如為合資格藥明生物技術股東，請使用本申請表格

倘閣下擬申請保證配額以外的超額預留股份，則須交回經填妥並簽署的申請超額預留股份之藍色申請表格，並單獨匯款足額支付所申請超額預留股份的應付股款。倘閣下擬申請相等於閣下的保證配額的預留股份數目，閣下應：(i)填妥並簽署申請表格；及(ii)提交一張支票（或銀行本票），金額須為申請表格乙欄所印列的確切匯款金額。

倘閣下使用藍色申請表格申請超額預留股份，閣下應：(i)填寫所申請的超額預留股份數目及應支付的金額（誠如申請表格列表所載者）；(ii)填寫並簽署申請表格；及(iii)提交一張獨立開出的支票（或銀行本票），金額須為閣下在申請表格填寫的相同金額。閣下擬申請的超額預留股份數目必須為申請表格列表所載數目之一（香港結算代理人除外）。倘申請的超額預留股份數目並非申請表格列表所載的其中一個數目，則超額申請可被拒絕受理。

2. 申請時應繳款項相等於所申請的預留股份數目乘以發售價每股發售股份20.60港元另加1%經紀佣金、0.0027%證監會交易徵費、0.00565%聯交所交易費及0.00015%會財局交易徵費。為方便閣下參考，本申請表格列表列出申請若干數目的預留股份時應繳款項。

謹請閣下注意，保證配額可能並非完整買賣單位500股股份之完整倍數股份。概不保證閣下最終之股份總持有量將為500股股份之完整倍數。

3. 請填妥並簽署申請表格。僅接納親筆簽名。
4. 支票或銀行本票須緊釘於表格。閣下必須以一張支票或一張銀行本票支付預留股份的申請款項。每份申請均須附帶一張獨立支票或銀行本票。

如以支票繳付款項，該支票必須：

- 為港元支票；
- 由香港的港元銀行賬戶開出；
- 顯示閣下的賬戶名稱，而該戶名必須預印於支票，或由有關銀行授權人在該支票背面簽署證明戶名。該賬戶名必須與閣下於本表格上的姓名相同。如屬聯名申請，則賬戶名稱必須與排名首位申請人的名稱相同；
- 註明抬頭人為「中國銀行（香港）代理人有限公司－藥明合聯生物技術優先發售」；
- 劃線註明「只准入抬頭人賬戶」；及
- 不得為期票。

下列情況將導致申請可能不獲受理：

- 支票不符合所有上述規定；或
- 支票首次過戶時不獲兌現。

如以銀行本票繳付款項，該本票必須：

- 為港元；
- 由香港持牌銀行發出，並由發出本票銀行的授權人在本票背面簽署證明閣下姓名。本票背面所顯示姓名須與本申請表格所填寫的姓名相同。如屬聯名申請，本票背面所顯示姓名必須與排名首位申請人的姓名相同；

- 註明抬頭人為「中國銀行（香港）代理人有限公司－藥明合聯生物技術優先發售」；
- 劃線註明「只准入抬頭人賬戶」；及
- 不得為期票。

如閣下的支票或銀行本票不符合上述所有規定，則閣下的申請可能遭拒絕受理。

5. 將本申請表格對摺一次，然後投入香港中央證券登記有限公司（地址為香港灣仔皇后大道東183號合和中心17M樓）的特設收集箱。

6. 閣下可於下列時間遞交本申請表格：

2023年11月7日（星期二）— 上午九時正至下午四時三十分

2023年11月8日（星期三）— 上午九時正至下午四時三十分

2023年11月9日（星期四）— 上午九時正至下午四時三十分

2023年11月10日（星期五）— 上午九時正至中午十二時正

7. 遞交申請的截止時間是2023年11月10日（星期五）中午十二時正，如該日並無開始登記認購申請，則為下一日開始登記認購申請的中午十二時正。本公司將於當日上午十一時四十五分至中午十二時正期間開始登記認購申請，惟須視乎當日天氣情況而定。

倘香港於2023年11月10日（星期五）上午九時正至中午十二時正期間任何時間發出：

- 八號或以上熱帶氣旋警告信號，或
- 「黑色」暴雨警告，及／或
- 極端情況，

將不會開始辦理申請登記，而改為在下一個於上午九時正至中午十二時正期間任何時間香港再無發出任何該等警告的營業日的上午十一時四十五分至中午十二時正期間開始辦理申請登記。營業日指星期六、星期日或香港公眾假期以外的日子。

8. 本公司保留將閣下的一切或任何股款過戶的權利，然而，閣下的支票或銀行本票不會於2023年11月10日（星期五）中午十二時正前過戶。閣下不會就已繳付款項獲發收據。本公司將保留閣下的申請股款的任何應計利息。在閣下的支票或銀行本票過戶前，本公司亦有權保留任何股票及／或任何多收的申請股款或退款。

BLUE FORM

Please use this Application Form if you are a Qualifying WXB Shareholder

Personal Data

Personal Information Collection Statement

This Personal Information Collection Statement informs the applicant for, and holder of, Hong Kong Offer Shares, of the policies and practices of the Company and its Hong Kong Share Registrar in relation to personal data and the Personal Data (Privacy) Ordinance (Chapter 486 of the Laws of Hong Kong) (the “**Ordinance**”).

1. Reasons for the collection of your personal data

It is necessary for applicants and registered holders of securities to supply correct personal data to the Company or its agents and the Hong Kong Share Registrar when applying for securities or transferring securities into or out of their names or in procuring the services of the Hong Kong Share Registrar.

Failure to supply the requested data may result in your application for securities being rejected, or in delay or the inability of the Company or its Hong Kong Share Registrar to effect transfers or otherwise render their services. It may also prevent or delay registration or transfers of the Hong Kong Offer Shares which you have successfully applied for and/or the dispatch of Share certificate(s) and/or refund cheque(s) to which you are entitled.

It is important that securities holders inform the Company and the Hong Kong Share Registrar immediately of any inaccuracies in the personal data supplied.

2. Purposes

The personal data of the securities holders may be used, held, processed, and/or stored (by whatever means) for the following purposes:

- processing your application and refund cheque, where applicable, verification of compliance with the terms and application procedures set out in this Application Form and the Prospectus and announcing results of allocation of the Hong Kong Offer Shares;
- compliance with applicable laws and regulations in Hong Kong and elsewhere;
- registering new issues or transfers into or out of the names of securities’ holders including, where applicable, HKSCC Nominees;
- maintaining or updating the register of securities’ holders of the Company;
- verifying securities holders’ identities;
- establishing benefit entitlements of securities’ holders of the Company, such as dividends, rights issues and bonus issues, etc.;
- distributing communications from the Company and its subsidiaries;
- compiling statistical information and securities’ holder profiles;
- disclosing relevant information to facilitate claims on entitlements; and

- any other incidental or associated purposes relating to the above and/or to enable the Company and the Hong Kong Share Registrar to discharge their obligations to securities’ holders and/or regulators and/or any other purposes to which the securities’ holders may from time to time agree.

3. Transfer of personal data

Personal data held by the Company and its Hong Kong Share Registrar relating to the securities holders will be kept confidential but the Company and its Hong Kong Share Registrar may, to the extent necessary for achieving any of the above purposes, disclose, obtain or transfer (whether within or outside Hong Kong) the personal data to, from or with any of the following:

- the Company’s appointed agents such as financial advisers and receiving bankers;
- where applicants for securities request a deposit into CCASS, HKSCC or HKSCC Nominees, who will use the personal data for the purposes of operating CCASS;
- any agents, contractors or third-party service providers who offer administrative, telecommunications, computer, payment or other services to the Company or the Hong Kong Share Registrar in connection with their respective business operation;
- the Stock Exchange, the SFC and any other statutory regulatory or governmental bodies or otherwise as required by laws, rules or regulations; and
- any persons or institutions with which the securities’ holders have or propose to have dealings, such as their bankers, solicitors, accountants or stockbrokers etc.

4. Retention of personal data

The Company and its Hong Kong Share Registrar will keep the personal data of the applicants and holders of securities for as long as necessary to fulfil the purposes for which the personal data were collected. Personal data which is no longer required will be destroyed or dealt with in accordance with the Ordinance.

5. Access to and correction of personal data

Securities holders have the right to ascertain whether the Company or the Hong Kong Share Registrar hold their personal data, to obtain a copy of that data, and to correct any data that is inaccurate. The Company and the Hong Kong Share Registrar have the right to charge a reasonable fee for the processing of such requests.

All requests for access to data or correction of data should be addressed to us, at our registered address disclosed in the section headed “Corporate Information” of the Prospectus or as notified from time to time, for the attention of the company secretary, or our Hong Kong Share Registrar for the attention of the privacy compliance officer.

By signing an Application Form or by giving electronic application instructions to HKSCC, you agree to all of the above.

藍表

閣下如為合資格藥明生物技術股東，請使用本申請表格

個人資料

個人資料收集聲明

此項個人資料收集聲明是向香港發售股份的申請人和持有人說明有關本公司及其香港證券登記處有關個人資料和香港法例第486章《個人資料(私隱)條例》(「條例」)方面的政策和慣例。

1. 收集閣下個人資料的原因

證券申請人及登記持有人以本身名義申請證券或轉讓或受讓證券時或尋求香港證券登記處的服務時，必須向本公司或其代理及香港證券登記處提供正確的個人資料。

未能提供所要求的資料可能導致閣下申請證券被拒或延遲，或本公司或其香港證券登記處無法落實轉讓或提供服務。此舉也可能妨礙或延遲登記或轉讓閣下成功申請的香港發售股份及／或寄發閣下應得的股票及／或退款支票。

證券持有人所提供的個人資料如有任何錯誤，須立即通知本公司及香港證券登記處。

2. 目的

證券持有人的個人資料可以任何方式被採用、持有、處理及／或保存，以作下列用途：

- 處理閣下的申請及退款支票(如適用)、核實是否符合本申請表格及招股章程載列的條款和申請程序以及公佈香港發售股份的分配結果；
- 遵守香港及其他地區的適用法律及法規；
- 以證券持有人(包括香港結算代理人(如適用))的名義登記新發行證券或轉讓或受讓證券；
- 存置或更新本公司證券持有人的名冊；
- 核實證券持有人的身份；
- 確定本公司證券持有人的受益權利，例如股息、供股和紅股等；
- 分發本公司及其附屬公司的通訊；
- 編製統計數據和證券持有人資料；
- 披露有關資料以便就權益索償；及

- 與上述有關的任何其他附帶或相關目的及／或使本公司及香港證券登記處能履行對證券持有人及／或監管機構承擔的責任及／或證券持有人可能不時同意的任何其他目的。

3. 轉交個人資料

本公司及其香港證券登記處所持有關證券持有人的個人資料將會被保密，但本公司及其香港證券登記處可以在為達到上述任何目的之必要情況下，向下列任何人士披露、獲取或轉交(無論在香港境內或境外)有關個人資料：

- 本公司委任的代理，例如財務顧問及收款銀行；
- (如證券申請人要求將證券存於中央結算系統)香港結算或香港結算代理人，彼等將會就中央結算系統的運作使用有關個人資料；
- 向本公司或香港證券登記處提供與其各自業務營運有關的行政、電訊、電腦、付款或其他服務的任何代理、承包商或第三方服務供應商；
- 聯交所、證監會及任何其他法定監管機關或政府部門或法律、規則或法規另行規定者；及
- 證券持有人與其進行或擬進行交易的任何人士或機構，例如彼等的銀行、律師、會計師或股票經紀等。

4. 保留個人資料

本公司及其香港證券登記處將按收集個人資料所需的用途保留證券申請人及持有人的個人資料。無需保留的個人資料將會根據條例銷毀或處理。

5. 查閱和更正個人資料

證券持有人有權確認本公司或香港證券登記處是否持有其個人資料、索取有關資料的副本並更正任何不準確資料。本公司和香港證券登記處有權就處理有關要求收取合理費用。所有查閱資料或更正資料的要求應按招股章程「公司資料」一節所披露或不時通知的本公司註冊地址送交公司秘書，或向本公司香港證券登記處的個人資料私隱事務主任提出。

閣下簽署申請表格或向香港結算發出電子認購指示，即表示同意上述各項。